Microbix Announces Annual and Special Meeting Voting Results
March 31 2022 - 7:00AM
Microbix Biosystems Inc. (
TSX: MBX, OTCQB: MBXBF,
Microbix®), a life sciences innovator and exporter,
announces the voting results from its Annual and Special Meeting of
Shareholders (the “
Meeting”) which was held on
March 30, 2022.
At the Meeting, 44.84% of the issued and
outstanding shares were represented. Shareholders voted in favour
of all resolutions brought before the Meeting. Details of all
resolutions that were voted upon are set-out in the Management
Information Circular (the “Circular”) dated
February 18, 2022. The Circular is available on Microbix’s website
(www.microbix.com) and on SEDAR (www.sedar.com).
All of the board of directors nominees listed in
the Circular were elected as directors of Microbix. The results of
the vote were as follows:
Nominee |
Votes For |
% Votes For |
Withheld |
% Withheld |
Peter M. Blecher |
59,238,916 |
99.69% |
|
186,570 |
0.31% |
|
Mark A. Cochran |
58,999,416 |
99.28% |
|
426,070 |
0.72% |
|
Vaughn C. Embro-Pantalony |
58,813,416 |
98.97% |
|
612,070 |
1.03% |
|
Cameron L. Groome |
58,256,018 |
98.03% |
|
1,169,468 |
1.97% |
|
Martin Marino |
59,257,416 |
99.72% |
|
168,070 |
0.28% |
|
Joseph D. Renner |
59,257,416 |
99.72% |
|
168,070 |
0.28% |
|
Jennifer Stewart |
59,260,157 |
99.72% |
|
165,329 |
0.28% |
|
|
|
|
|
|
|
|
Shareholders also approved a resolution
re-appointing Microbix’s auditors, Ernst & Young LLP, with
99.97% of the votes cast in favour.
The slides of management’s presentation at the
Meeting have been posted at www.microbix.com.
About Microbix
BiosystemsMicrobix develops proprietary biological
technology solutions for human health and well-being, with over 100
skilled employees and sales nearing C$ 2.0 million per month. It
makes a wide range of critical biological materials for the global
diagnostics industry, notably antigens for immunoassays and its
laboratory quality assessment products (QAPs™) that support
clinical lab proficiency testing, enable assay development and
validation, or help ensure the quality of clinical diagnostic
workflows. Microbix antigens enable the antibody tests of over 100
international diagnostics companies, while its QAPs are sold to
clinical laboratory accreditation organizations, diagnostics
companies, and clinical laboratories. Microbix QAPs are now
available in over 30 countries, distributed by 1WA (Oneworld
Accuracy Inc.), Alpha-Tec Systems, Inc., Diagnostic International
Distribution SpA., Labquality Oy, The Medical Supply Company of
Ireland, R-Biopharm AG, SDT Molecular Pte Ltd, Seegene Canada Inc.,
and Thomas Scientific LLC. Microbix is ISO 9001 and 13485
accredited, U.S. FDA registered, Australian TGA registered, Health
Canada establishment licensed, and provides CE marked products.
Microbix also applies its biological expertise
and infrastructure to develop other proprietary products and
technologies, most notably viral transport medium (DxTM™) to
stabilize patient samples for lab-based molecular diagnostic
testing and Kinlytic® urokinase, a biologic thrombolytic drug used
to treat blood clots. Microbix is traded on the TSX and OTCQX, and
headquartered in Mississauga, Ontario, Canada.
Forward-Looking InformationThis
news release or the referenced management presentation may include
“forward-looking information,” as such term is defined in
applicable securities laws. Forward-looking information includes,
without limitation, all discussion regarding Microbix products,
Microbix’s business and business results, goals or outlook, risks
associated with financial results and stability, development
projects such as those referenced in its corporate presentations,
regulatory compliance and approvals, sales to domestic or foreign
jurisdictions, engineering and construction, production (including
control over costs, quality, quantity and timeliness of delivery),
foreign currency and exchange rates, maintaining adequate working
capital and raising further capital on acceptable terms or at all,
and other similar statements concerning anticipated future events,
conditions or results that are not historical facts. These
statements reflect management’s current estimates, beliefs,
intentions and expectations; they are not guarantees of future
performance. The Company cautions that all forward looking
information is inherently uncertain and that actual performance may
be affected by a number of material factors, many of which are
beyond the Company’s control. Accordingly, actual future events,
conditions and results may differ materially from the estimates,
beliefs, intentions and expectations expressed or implied in the
forward-looking information. All statements are made as of the date
of this news release and represent the Company’s judgement as of
the date of this new release, and the Company is under no
obligation to update or alter any forward-looking information.
Cameron Groome, CEO(905) 361-8910 |
Jim Currie, CFO(905) 361-8910 |
Deborah Honig, Investor RelationsAdelaide Capital Markets(647)
203-8793 ir@microbix.com |
|
Jim Macdonald,Investor RelationsTorrey Hills Capital(858)
456-7300jm@sdthc.com |
|
Copyright © 2022 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, and QAPs™ are trademarks of Microbix
Biosystems Inc.
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Oct 2023 to Oct 2024